Literature DB >> 8985766

A prolonged outbreak of methicillin-resistant Staphylococcus aureus in the burn unit of a tertiary medical center.

P A Meier1, C D Carter, S E Wallace, R J Hollis, M A Pfaller, L A Herwaldt.   

Abstract

OBJECTIVE: To report an outbreak of methicillin-resistant Staphylococcus aureus (MRSA) in our burn unit and the steps we used to eradicate the organism. DESIGN AND
SETTING: Outbreak investigation in the burn unit of a 900-bed tertiary-care medical center. OUTBREAK: Between March and June 1993, MRSA was isolated from 10 patients in our burn unit. All isolates had identical antibiograms and chromosomal DNA patterns. CONTROL MEASURES: Infection control personnel encouraged healthcare workers to wash their hands after each patients contact. The unit cohorted all infected or colonized patients, placed each affected patient in isolation, and, if possible, transferred the patient to another unit. Despite these measures, new cases occurred. Infection control personnel obtained nares cultures from 56 healthcare workers, 3 of whom carried the epidemic MRSA strain. One healthcare worker cared for six affected patients, and one cared for five patients. We treated the three healthcare workers with mupirocin. Subsequently, no additional patients became colonized or infected with the epidemic MRSA strain.
CONCLUSIONS: The outbreak ended after we treated healthcare workers who carried the epidemic strain with mupirocin. This approach is not appropriate in all settings. However, we felt it was justified in this case because of a persistent problem after less intrusive measures.

Entities:  

Mesh:

Year:  1996        PMID: 8985766     DOI: 10.1086/647239

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  12 in total

Review 1.  Health service careers for people with cystic fibrosis.

Authors:  Sarah Walters
Journal:  J R Soc Med       Date:  2002       Impact factor: 5.344

Review 2.  [Methicillin-resistant Staphylococcus aureus. Types of resistance and clinical consequences].

Authors:  U Geipel; M Herrmann
Journal:  Anaesthesist       Date:  2005-02       Impact factor: 1.041

3.  Enteral vancomycin controls methicillin-resistant Staphylococcus aureus endemicity in an intensive care burn unit: a 9-year prospective study.

Authors:  Enrique Cerdá; Ana Abella; Miguel A de la Cal; José A Lorente; Paloma García-Hierro; Hendrick K F van Saene; Inmaculada Alía; Ainhoa Aranguren
Journal:  Ann Surg       Date:  2007-03       Impact factor: 12.969

4.  2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Health Care Settings.

Authors:  Jane D Siegel; Emily Rhinehart; Marguerite Jackson; Linda Chiarello
Journal:  Am J Infect Control       Date:  2007-12       Impact factor: 2.918

Review 5.  MRSA and the environment: implications for comprehensive control measures.

Authors:  N Cimolai
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-02-14       Impact factor: 3.267

Review 6.  Topical antimicrobials for burn wound infections.

Authors:  T Dai; Y Y Huang; S K Sharma; J T Hashmi; D B Kurup; M R Hamblin
Journal:  Recent Pat Antiinfect Drug Discov       Date:  2010-06

7.  Randomized, placebo-controlled, double-blind trial to evaluate the efficacy of mupirocin for eradicating carriage of methicillin-resistant Staphylococcus aureus.

Authors:  S Harbarth; S Dharan; N Liassine; P Herrault; R Auckenthaler; D Pittet
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

Review 8.  Burn wound infections.

Authors:  Deirdre Church; Sameer Elsayed; Owen Reid; Brent Winston; Robert Lindsay
Journal:  Clin Microbiol Rev       Date:  2006-04       Impact factor: 26.132

9.  Infection control in severely burned patients.

Authors:  Yusuf Kenan Coban
Journal:  World J Crit Care Med       Date:  2012-08-04

10.  Staphylococcus aureus Carriage and Health Care-acquired Infection.

Authors:  Fu-Yu Chiang; Michael Climo
Journal:  Curr Infect Dis Rep       Date:  2002-12       Impact factor: 3.663

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.